I know from my discussions with DXB mgt that the respect is mutual OVF. I value your posts too, thank you.
Also, a lot of discussion here about the Pitt St Research and valuation of 58-77c
The report clearly states this is for DMX200 AND FSGS only. No other indications for 200, no value on 700, and most importantly no value to its Receptor-HIT technology.
In my opinion, the real value is in the latter IP for big pharma looking for an NPD pipeline, not the shorter term hit from 200.
Good luck to those that trade the former, but I for one are here for the latter.
GLA.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
55.5¢ |
Change
0.010(1.83%) |
Mkt cap ! $323.1M | |||
| Open | High | Low | Value | Volume |
| 54.5¢ | 55.5¢ | 54.5¢ | $88.55K | 160.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 82270 | 55.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.0¢ | 1500 | 1 |
View Market Depth
| Last trade - 10.04am 25/06/2025 (20 minute delay) ? |
| DXB (ASX) Chart |